Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma.

Tsimafeyeu I, Sultanbaev A, Dubovichenko D, Murzalina M, Volkov A, Orlova R, Utyashev I, Malina G, Gluzman M

DOI: 10.37349/etat.2025.1002305
Published: 2025
Container: Exploration of targeted anti-tumor therapy
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.37349/etat.2025.1002305,
  title = {Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma.},
  author = {Tsimafeyeu I and Sultanbaev A and Dubovichenko D and Murzalina M and Volkov A and Orlova R and Utyashev I and Malina G and Gluzman M},
  year = {2025},
  journal = {Exploration of targeted anti-tumor therapy},
  doi = {10.37349/etat.2025.1002305},
  url = {https://doi.org/10.37349/etat.2025.1002305}
}

RIS

TY  - JOUR
TI  - Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma.
AU  - Tsimafeyeu I
AU  - Sultanbaev A
AU  - Dubovichenko D
AU  - Murzalina M
AU  - Volkov A
AU  - Orlova R
AU  - Utyashev I
AU  - Malina G
AU  - Gluzman M
PY  - 2025
JO  - Exploration of targeted anti-tumor therapy
DO  - 10.37349/etat.2025.1002305
UR  - https://doi.org/10.37349/etat.2025.1002305
ER  -

APA

I, T., A, S., D, D., M, M., A, V., R, O., I, U., G, M., & M, G. (2025). Real-world outcomes of lenvatinib plus pembrolizumab in intermediate- and poor-risk metastatic renal cell carcinoma.. Exploration of targeted anti-tumor therapy. https://doi.org/10.37349/etat.2025.1002305

Source records

pubmed · retrieved 2026-09-26T21:47:32.250Z